BOEHRINGER EXPANDS DRUG MANUFACTURING CAPABILITIES IN CHINA

The main activity of our company is providing pharmaceutical enterprises with high-quality substances and consumables..

BOEHRINGER EXPANDS DRUG MANUFACTURING CAPABILITIES IN CHINA
Ask question
Our specialists answer any question about your inquiry
6 July 2018
      Boehringer Ingelheim has added a new filling line to its Oasis facility in Shanghai, China in order to expand and consolidate its contract drug manufacturing capabilities.

      The expansion means the company’s contract manufacturing business Boehringer Ingelheim BioXcellence now has an isolator-based fill & finish line to carry out aseptic filling of liquids in vials.

      Meaning BioXcellence can offer all manufacturing activities for drug substance and drug product as well as associated quality control and assurance at its Shanghai manufacturing site.

      Boehringer Ingelheim Biopharmaceuticals China general manager Luo Jiali said: “I believe that our customers will benefit from this investment by receiving high quality drug substance and drug product from one source as a convenient pathway to deliver biopharmaceuticals to our customers and, in the end, to patients.”

      The company said that the new fill & finish line is part of its plan to provide a one-stop-shop for contract development and manufacturing of biopharmaceutical medicines at its commercial facility.

      Boehringer Ingelheim BioXcellence operates in Germany, Austria, the US and China. It delivers customised contract development and manufacturing services.

      The company provides complete product technology, including DNA, fill and finish, while assuring supply throughout the whole product lifecycle via the transfer of customer projects at any stage and delivery to nearly any scale.

      Boehringer’s Chinese subsidiary was established in 1994 and has more than 3500 employees. It provides all-round biopharmaceutical contract manufacturing solutions and services, including process development, clinical trials and product supply to both domestic and international clients.

      The company initiated operations at the Shanghai biopharmaceuticals site last year, with an investment of €70m during the first phase.